Relationship between IL28B gene rs8099917 polymorphism and SVR in Turkish patients with hepatitis C virus genotype 1.

AKKIZ, HİKMET; Akgollu, Ersin; Bekar, Aynur; Yildirim, Selcuk; Sandikci, Macit; Ulger, YAKUP; Kaya, Berrin; KURAN, SEDEF; ÜSKÜDAR, OĞUZ

doi:10.1016/j.clinre.2015.02.008

Relationship between IL28B gene rs8099917 polymorphism and SVR in Turkish patients with hepatitis C virus genotype 1.

Atıf İçin Kopyala

AKKIZ H., Akgollu E., Bekar A., Yildirim S., Sandikci M., Ulger Y., ...Daha Fazla

Clinics and research in hepatology and gastroenterology, cilt.39, sa.6, ss.711-7, 2015 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 39 Sayı: 6
Basım Tarihi: 2015
Doi Numarası: 10.1016/j.clinre.2015.02.008
Dergi Adı: Clinics and research in hepatology and gastroenterology
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.711-7
Çukurova Üniversitesi Adresli: Evet

Özet

Background and objective: The hepatitis C virus (HCV) which infects 3% of the world's population is a global challenge. Recently, genome-wide association studies (GWAS) have identified that the IL28B gene rs8099917 polymorphism was associated with the response to the pegylated-interferon alpha/ribavirin (PegIFN alpha/RBV) combination therapy in patients infected with HCV genotype 1. IL28B gene rs8099917 polymorphism should be determined before beginning treatment of HCV-infected patients to predict an individual's response. The aims of this study were to analyze the correlation between IL28B gene rs8099917 (T/G) polymorphism and PegIFN alpha/RBV therapy outcome in the Turkish population.